Drugs / Cell culture-derived trivalent subunit influenza vaccine
Cell culture-derived trivalent subunit influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00492063 | Sep → Dec 2004 | influenza | Novartis Vaccines | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell culture-derived trivalent subunit influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00492063 ↗ |
| Known as | CCIV | “Here, we describe a novel cell culture-derived influenza vaccine (CCIV) produced in Madin-Darby canine kidney cells.” PMID 19673651 ↗ Sep 2009 |
| Known as | cTIV | “Cell culture-derived trivalent subunit influenza vaccine (cTIV)” NCT00492063 ↗ |
| Modality | Vaccine | “cell culture-derived influenza vaccine (cTIV)” NCT00492063 ↗ |
| Route | Intramuscular | “received a single intramuscular vaccination” PMID 19673651 ↗ Sep 2009 |